Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Oncotest, Debiopharm announce successful biomarker projects
June 2013
SHARING OPTIONS:

LAUSANNE, Switzerland—Oncotest GmbH and Debiopharm Group have announced the completion of the first biomarker projects at Oncotest. A recent study generated pharmacological data with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts, which was then correlated with Oncotest's genomic and transcriptomic data, resulting in the identification of several predictive biomarker candidates, including a gene signature.
 
 
"Reliable preclinical models are key success factors in drug development. We believe that technologies based on the direct use of patient tumors have game-changer potential in translational research in oncology," Dr. Hiroaki Tanaka, personalized medicine director at Debiopharm, said in a press release. "We are happy to collaborate with Oncotest … and we are looking forward to extending our partnership even further towards the achievement of personalized medicine."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.